Based on this finding, it is plausible to consider aiming D2R-NMDAR (NR2B containing) heteroreceptor complexes by co-treatment of a NR2B-selective NMDA antagonist with an mGluR5 antagonist/negative allosteric mGluR5 modulator to treat PD. This evidence concerns the gene GRM5 and Parkinson disease.